Lumida
/IRWD
⌘K
Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

IRWD
$4.08USD+2.77%+0.11 today

MARKET CAP

674.2M

P/E (TTM)

5.1x

FWD P/E

3.1x

DAY RANGE

$4 – $4

52W RANGE

$1
$6

AI Summary

Stalk
StalkMedium

IRWD remains in a Stage 2 advancing context with price consolidating near the rising 200-day SMA. Medium-term bias stays bullish, but short-term momentum is negative as price trades below the 9/20-day EMA cluster. Execution is deferred: stalk long on pullbacks into the 9/20 EMA zone (~4.15–4.18) or holds at the 200-day SMA (~3.95). The long-term uptrend on the rising 200-day SMA remains intact; a sustained break below that level would invalidate the bullish view.

  • Q2 revenue $113M up 33% YoY, driven by Linzess’s 14% sales jump to $282.3M.
  • Full-year Linzess net sales guidance raised to $1.15–$1.20B on mid-single-digit demand growth.
  • Revenue tied almost exclusively to Linzess, exposing cash flow to demand swings.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$413.8M$410.6M$442.7M$351.4M$296.2M
YoY %+6.2%-0.8%+7.8%-20.6%-15.7%
P / Sales4.6x5.6x4.4x2.0x1.9x
EV / Sales4.4x5.1x6.0x3.6x3.4x
Gross Profit, Adj.$413.8M$410.6M$442.7M$351.4M$296.2M
YoY %+7.1%-0.8%+7.8%-20.6%-15.7%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit4.4x5.1x6.0x3.6x3.4x
EBITDA, Adj.$233.8M$251.8M$169.9M$97.7M$120.6M
YoY %+44.4%+7.7%-32.5%-42.5%+23.4%
Margin %56.5%61.3%38.4%27.8%40.7%
EV / EBITDA7.8x8.3x15.6x13.0x8.2x
EBIT$232.3M$250.3M$-945.4M$93.1M$98.5M
YoY %+62.5%+7.8%-477.7%+109.8%+5.8%
Margin %56.1%61.0%-213.5%26.5%33.3%
EV / EBIT7.8x8.3x-2.8x13.7x10.1x
Net Income$528.4M$175.1M$-1.0B$880,000$24.0M
YoY %+397.7%-66.9%-672.5%+100.1%+2629.2%
Net Margin127.7%42.6%-226.4%0.3%8.1%
EPS (GAAP)$3.21$0.96-$6.45$0.01$0.15
YoY %+386.4%-70.1%-771.9%+100.2%+1400.0%